PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells

This publication has 41 references indexed in Scilit:

• In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway
  Blood, 2002
• IL-1β expression in IgM monoclonal gammopathy and its relationship to multiple myeloma
  Leukemia, 2002
• The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells
  International Journal of Cancer, 2001
• Circulating IL‐6‐type cytokines and sIL‐6R in patients with multiple myeloma
  British Journal of Haematology, 1999
• Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating study
  British Journal of Haematology, 1998
• Syndecan-1 Expression on Malignant Cells from the Blood and Marrow of Patients with Plasma Cell Proliferative Disorders and B-Cell Chronic Lymphocytic Leukemia
  Leukemia & Lymphoma, 1998
• An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-I
  Oncogene, 1997
• C-kit ligand (SCF) in human multiple myeloma cells
  Leukemia & Lymphoma, 1996
• The gp 130 family cytokines IL‐6, LIF and OSM but not IL‐11 can reverse the anti‐proliferative effect of dexamethasone on human myeloma cells
  British Journal of Haematology, 1995
• Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.
  The Journal of Experimental Medicine, 1994